By daegloe - 2 days ago
Showing first level comment(s)
For immunotherapy to fulfill its promise. Every type of response for every category of tumor cell must be decoded. As well as every effective ligand to boost immune cell strategy.
Currently there are only a handful of therapies approved globally. Among hundreds of ongoing trials that need patients to sign up.
The inefficiency in the marketplace landscape then is a disconnect. Between patients for whom there may be a potential cure. And researchers who lack the reach to connect with them.
There is probably potential for a startup here that connects the two ;)
ArtWomb - a day ago
"Sequestration of T cells in bone marrow is therefore a tumor-adaptive mode of T cell dysfunction, whose reversal may constitute a promising immunotherapeutic adjunct."
rfinney - 2 days ago
The abstract states that the loss of S1P1 is tumor imposed, but not having access to the paper, I don't know what they mean by that.
tynpeddler - 18 hours ago
"Duke scientists discovered an abundance of missing T-cells trapped within the bone marrow."
"an abundance of missing"
I know everyone makes mistakes, but I can't even fathom writing this sentence and thinking it sounded good
yhoneycomb - a day ago